MX2018011491A - Disposiciones de secuencia y secuencias para presentacion de neoepitopos. - Google Patents
Disposiciones de secuencia y secuencias para presentacion de neoepitopos.Info
- Publication number
- MX2018011491A MX2018011491A MX2018011491A MX2018011491A MX2018011491A MX 2018011491 A MX2018011491 A MX 2018011491A MX 2018011491 A MX2018011491 A MX 2018011491A MX 2018011491 A MX2018011491 A MX 2018011491A MX 2018011491 A MX2018011491 A MX 2018011491A
- Authority
- MX
- Mexico
- Prior art keywords
- sequences
- sequence arrangements
- neoepitope presentation
- polytope
- neoepitope
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 230000032258 transport Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/002—Vectors comprising a special translation-regulating system controllable or inducible
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Evolutionary Biology (AREA)
- Medical Informatics (AREA)
Abstract
Se presentan sistemas y metodos que permiten la seleccion de neoepitopos tumorales que despues se usan para generar un politopo recombinante que se optimiza para el trafico y procesamiento adecuados. En los metodos preferidos, el politopo se codifica en un sistema de expresion viral que se usa como un agente terapeutico.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662312974P | 2016-03-24 | 2016-03-24 | |
US201662313621P | 2016-03-25 | 2016-03-25 | |
US201662314366P | 2016-03-28 | 2016-03-28 | |
PCT/US2017/023894 WO2017222619A2 (en) | 2016-03-24 | 2017-03-23 | Sequence arrangements and sequences for neoepitope presentation |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018011491A true MX2018011491A (es) | 2019-08-01 |
Family
ID=60157677
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018011491A MX2018011491A (es) | 2016-03-24 | 2017-03-23 | Disposiciones de secuencia y secuencias para presentacion de neoepitopos. |
Country Status (12)
Country | Link |
---|---|
US (2) | US11154597B2 (es) |
EP (1) | EP3475434A4 (es) |
JP (1) | JP2019513021A (es) |
KR (1) | KR20180117227A (es) |
CN (1) | CN109563521A (es) |
AU (1) | AU2017281126A1 (es) |
CA (1) | CA3018741A1 (es) |
IL (1) | IL261813A (es) |
MX (1) | MX2018011491A (es) |
SG (1) | SG11201807770RA (es) |
TW (1) | TW201742923A (es) |
WO (1) | WO2017222619A2 (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180117227A (ko) | 2016-03-24 | 2018-10-26 | 난트셀, 인크. | 네오에피토프 제시를 위한 시퀀스들 및 시퀀스 배열들 |
WO2018094309A2 (en) * | 2016-11-21 | 2018-05-24 | Nant Holdings Ip, Llc | Fractal combination therapy |
US11229668B2 (en) | 2017-02-07 | 2022-01-25 | Nantcell, Inc. | Maximizing T-cell memory and compositions and methods therefor |
US11779637B2 (en) | 2017-04-24 | 2023-10-10 | Nantcell, Inc. | Targeted neoepitope vectors and methods therefor |
US20200225229A1 (en) * | 2017-09-25 | 2020-07-16 | Nant Holdings Ip, Llc | Validation of Neoepitope Presentation |
KR20200055136A (ko) * | 2017-10-05 | 2020-05-20 | 난트셀, 인크. | Th1 및 Th2를 자극하는 다가 항원 (MULTIVALENT ANTIGENS STIMULATING TH1 AND TH2) |
US20200354730A1 (en) * | 2017-11-27 | 2020-11-12 | Nantcell, Inc. | Improved Yeast Polytope Vaccine Compositions And Methods |
KR20200135986A (ko) * | 2018-03-19 | 2020-12-04 | 멀티비르 인코포레이티드 | 종양 억제인자 유전자 치료 및 cd122/cd132 작용제를 포함하는 암 치료를 위한 방법 및 조성물 |
US11267866B2 (en) | 2018-04-04 | 2022-03-08 | Nant Holdings Ip, Llc | Immunoglobulin complex comprising interleukin-15 |
US11564980B2 (en) | 2018-04-23 | 2023-01-31 | Nantcell, Inc. | Tumor treatment method with an individualized peptide vaccine |
TWI816603B (zh) * | 2018-04-23 | 2023-09-21 | 美商南特細胞公司 | 新抗原表位疫苗及免疫刺激組合物及方法 |
CA3100282A1 (en) | 2018-06-19 | 2019-12-26 | Nantcell, Inc. | Hiv treatment compositions and methods |
WO2020073045A1 (en) * | 2018-10-05 | 2020-04-09 | Nantcell, Inc. | Cd40 and cd40l combo in an adenovirus vaccine vehicle |
EP3938495A4 (en) * | 2019-03-15 | 2023-04-26 | Nantcell, Inc. | RECOMBINANT ERIL-15 NK CELLS |
CN111755073B (zh) * | 2020-05-31 | 2022-11-15 | 复旦大学 | 基于转录组的pd-1疗法治疗效果预测系统 |
EP4229420A1 (en) * | 2020-10-19 | 2023-08-23 | NantBio, Inc. | Arrayed peptide neoepitope generator |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7157091B1 (en) | 1999-06-18 | 2007-01-02 | Ludwig Institute For Cancer Research | MAGE-A1 peptides presented by HLA class II molecules |
KR100555211B1 (ko) | 2002-07-16 | 2006-03-03 | 주식회사 팬제노믹스 | 항암효과를 갖는 Her-2/neu DNA 백신 |
US7179797B2 (en) | 2002-09-27 | 2007-02-20 | Wisconsin Alumni Research Foundation | Methods and compositions for treating prostate cancer using DNA vaccines |
CA2518569C (en) | 2003-03-10 | 2011-11-15 | Expression Pathology, Inc. | Liquid tissue preparation from histopathologically processed biological samples, tissues and cells |
US20050095648A1 (en) | 2003-10-30 | 2005-05-05 | Mario Geysen | Method for designing linear epitopes and algorithm therefor and polypeptide epitopes |
HUE038768T2 (hu) | 2005-02-18 | 2018-11-28 | Abraxis Bioscience Llc | Terápiás szerek kombinációi, valamint beadásukra szolgáló módszerek, és kombinációs terápia |
CN101291658B (zh) | 2005-08-31 | 2014-04-16 | 阿布拉科斯生物科学有限公司 | 用于制备稳定性增加的水难溶性药物的组合物和方法 |
TWI417114B (zh) | 2005-08-31 | 2013-12-01 | Abraxis Bioscience Llc | 具有增強穩定性之弱水溶性藥物之組合物及其製備方法 |
JP5198290B2 (ja) | 2006-02-02 | 2013-05-15 | グローブイミューン,インコーポレイテッド | 免疫反応を誘発する酵母ベースワクチン |
WO2009006479A2 (en) | 2007-07-02 | 2009-01-08 | Etubics Corporation | Methods and compositions for producing an adenovirus vector for use with multiple vaccinations |
US20110071214A1 (en) | 2008-05-14 | 2011-03-24 | Gregory John Allen | Methods and compositions for the treatment of cancer |
JP5759980B2 (ja) | 2009-04-17 | 2015-08-05 | グローブイミューン,インコーポレイテッド | 癌および感染症に対する免疫療法組成物の組み合わせ |
WO2011139345A2 (en) | 2010-04-29 | 2011-11-10 | The Regents Of The University Of California | Pathway recognition algorithm using data integration on genomic models (paradigm) |
US10192641B2 (en) | 2010-04-29 | 2019-01-29 | The Regents Of The University Of California | Method of generating a dynamic pathway map |
CN103180730B (zh) * | 2010-05-14 | 2016-03-02 | 综合医院公司 | 鉴定肿瘤特异性新抗原的组合物和方法 |
US9646134B2 (en) | 2010-05-25 | 2017-05-09 | The Regents Of The University Of California | Bambam: parallel comparative analysis of high-throughput sequencing data |
KR102042253B1 (ko) | 2010-05-25 | 2019-11-07 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Bambam:고처리율 서열분석 데이터의 병렬 비교 분석 |
HUE033491T2 (en) | 2011-03-17 | 2017-12-28 | Globeimmune Inc | Yeast-Brachyury immunotherapy |
WO2012138754A2 (en) | 2011-04-04 | 2012-10-11 | Beth Israel Deaconess Medical Center, Inc. | Mycobacterial vaccine vectors and methods of using the same |
CN105999250B (zh) | 2011-05-24 | 2020-03-10 | 生物技术Rna制药有限公司 | 用于癌症的个体化疫苗 |
MX352892B (es) | 2011-08-17 | 2017-12-13 | Globeimmune Inc | Composiciones inmunoterapeuticas de levadura-mucina 1 (muc1) y usos de las mismas. |
CN102657864B (zh) * | 2012-04-28 | 2014-01-01 | 中国农业科学院兰州兽医研究所 | 一种口蹄疫疫苗的免疫佐剂及其应用 |
WO2014031178A1 (en) | 2012-08-24 | 2014-02-27 | Etubics Corporation | Replication defective adenovirus vector in vaccination |
WO2014082729A1 (en) * | 2012-11-28 | 2014-06-05 | Biontech Ag | Individualized vaccines for cancer |
WO2014168874A2 (en) | 2013-04-07 | 2014-10-16 | The Broad Institute, Inc. | Compositions and methods for personalized neoplasia vaccines |
KR20230076867A (ko) * | 2013-12-20 | 2023-05-31 | 더 브로드 인스티튜트, 인코퍼레이티드 | 신생항원 백신과의 병용 요법 |
JP6613312B2 (ja) * | 2014-10-14 | 2019-11-27 | ジ ユナイテッド ステイツ オブ アメリカ アズ リプリゼンティッド バイ ザ セクレタリー,デパートメント オブ ヘルス アンド ヒューマン サービシズ | 膵臓癌を処置するためのペプチドをベースとする方法 |
BR112017022845A2 (pt) | 2015-04-23 | 2018-07-17 | Nantomics, Llc | neoepítopos de câncer |
MX2017014700A (es) | 2015-05-20 | 2018-08-15 | Broad Inst Inc | Neoantigenos compartidos. |
TW201708536A (zh) | 2015-05-26 | 2017-03-01 | 艾法西斯公司 | 個人化的基於遞送載體之免疫療法及其用途 |
AU2016281958A1 (en) | 2015-06-24 | 2018-02-15 | Advaxis, Inc. | Manufacturing device and process for personalized delivery vector-based immunotherapy |
EP3341877B1 (en) | 2015-08-25 | 2023-05-10 | Nantomics, LLC | Systems and methods for high-accuracy variant calling |
IL258688B2 (en) | 2015-10-12 | 2023-04-01 | Nantomics Llc | Compositions and methods for cancer viral neoepitopes |
KR20180117227A (ko) | 2016-03-24 | 2018-10-26 | 난트셀, 인크. | 네오에피토프 제시를 위한 시퀀스들 및 시퀀스 배열들 |
WO2018094309A2 (en) | 2016-11-21 | 2018-05-24 | Nant Holdings Ip, Llc | Fractal combination therapy |
GB2557276A (en) | 2016-12-02 | 2018-06-20 | Nordic Semiconductor Asa | Voltage regulators |
US11779637B2 (en) | 2017-04-24 | 2023-10-10 | Nantcell, Inc. | Targeted neoepitope vectors and methods therefor |
-
2017
- 2017-03-23 KR KR1020187030362A patent/KR20180117227A/ko not_active Application Discontinuation
- 2017-03-23 EP EP17815840.8A patent/EP3475434A4/en not_active Withdrawn
- 2017-03-23 WO PCT/US2017/023894 patent/WO2017222619A2/en active Application Filing
- 2017-03-23 SG SG11201807770RA patent/SG11201807770RA/en unknown
- 2017-03-23 MX MX2018011491A patent/MX2018011491A/es unknown
- 2017-03-23 JP JP2018550347A patent/JP2019513021A/ja active Pending
- 2017-03-23 US US15/468,046 patent/US11154597B2/en active Active
- 2017-03-23 CA CA3018741A patent/CA3018741A1/en not_active Abandoned
- 2017-03-23 CN CN201780017324.8A patent/CN109563521A/zh active Pending
- 2017-03-23 AU AU2017281126A patent/AU2017281126A1/en not_active Abandoned
- 2017-03-24 TW TW106110045A patent/TW201742923A/zh unknown
-
2018
- 2018-09-16 IL IL261813A patent/IL261813A/en unknown
-
2020
- 2020-05-14 US US16/874,104 patent/US20200297830A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20200297830A1 (en) | 2020-09-24 |
CN109563521A (zh) | 2019-04-02 |
WO2017222619A2 (en) | 2017-12-28 |
CA3018741A1 (en) | 2017-12-28 |
EP3475434A4 (en) | 2020-07-29 |
WO2017222619A3 (en) | 2019-03-28 |
AU2017281126A1 (en) | 2018-10-04 |
EP3475434A2 (en) | 2019-05-01 |
JP2019513021A (ja) | 2019-05-23 |
SG11201807770RA (en) | 2018-10-30 |
US20170312351A1 (en) | 2017-11-02 |
US11154597B2 (en) | 2021-10-26 |
KR20180117227A (ko) | 2018-10-26 |
TW201742923A (zh) | 2017-12-16 |
IL261813A (en) | 2018-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018011491A (es) | Disposiciones de secuencia y secuencias para presentacion de neoepitopos. | |
MX2022004374A (es) | Composiciones de agonista de tlr9 e inhibidores de punto de control para usarse en la respuesta inmune contra el cancer. | |
MX2019005465A (es) | Metodo de tratamiento de un tumor inmunoterapeutico. | |
MX2018008426A (es) | Combinaciones anti-egfr para tratar tumores. | |
MX2023000320A (es) | Metodos para modular los niveles de farmaco en plasma mediante el uso de eritrohidroxibupropion. | |
PH12017500022A1 (en) | Carrier-antibody compositions and methods of making and using the same | |
MX2017003227A (es) | Terapias de combinacion de inhibidores de alk. | |
PH12017502103A1 (en) | Methods and kits for treating depression | |
PH12016501830A1 (en) | Inhibitors of c5a for the treatment of viral pneumonia | |
MX2020005446A (es) | Metodos para marcar una molecula deuterada o no deuterada y formulaciones farmaceuticas para tratamiento. | |
CO2017004932A2 (es) | Métodos para seleccionar una línea de células t y donador de la misma para terapia celular adoptiva | |
MX2018001755A (es) | Vacuna contra viruela para tratamiento del cancer. | |
GB201510771D0 (en) | Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer | |
MX2018008427A (es) | Combinaciones anti-cd20 para tratar tumores. | |
HK1253531A1 (zh) | 用於免疫治療的新型肽和肽組合物以及用於胰腺癌和其他癌症的支架產生方法 | |
NZ723884A (en) | Methods of treating alzheimer’s disease | |
MX2017004897A (es) | Cepas vacunales recombinantes de listeria y metodos para usar las mismas en la inmunoterapia contra el cancer. | |
MX2018004598A (es) | Cepas vacunales recombinantes de listeria y métodos para usar las mismas en la inmunoterapia contra el cáncer. | |
MX2018005544A (es) | Uso de agonistas del receptor tipo toll- 8 (tlr8) para tratar cancer. | |
MX2017011794A (es) | Composiciones y metodos para diagnosticos y tratamiento del cancer. | |
MX2018006996A (es) | Composiciones y metodos mejorados para la entrega viral de neoepitopos y usos de estos. | |
IN2014MU00303A (es) | ||
PH12018500254A1 (en) | Combinations of an ox40 antibody and a tlr4 modulator and uses thereof | |
EP3998341A3 (en) | Adenoviral vectors | |
PH12016501838A1 (en) | Compounds and their methods of use |